Amylin Pharmaceuticals Names Michael Hanley As Vice President of Discovery Research
October 31 2003 - 7:30AM
PR Newswire (US)
Amylin Pharmaceuticals Names Michael Hanley As Vice President of
Discovery Research SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ --
Amylin Pharmaceuticals, Inc. today announced that Michael Hanley,
Ph.D. has joined the Company as Vice President, Discovery Research.
Dr. Hanley has served on the Scientific Advisory Board of Amylin
since 1992 and for the last six months has served as a senior
scientific advisor to the Company. Dr. Hanley will oversee Amylin's
discovery research in the areas of research chemistry, in-vivo
modeling and cell and molecular biology. "Dr. Hanley brings an
outstanding record of accomplishment in academic research and
highly relevant experience in the development of research programs
for biotechnology organizations," commented Daniel M. Bradbury,
Chief Operating Officer for Amylin Pharmaceuticals, Inc. "He has
played an important role in guiding and refining the drug discovery
capabilities of Amylin since the Company's formation, and we are
pleased that he has agreed to lead our internal efforts to expand
our pipeline of drug candidates to treat metabolic diseases." From
1981 to 1997, Dr. Hanley held faculty positions at Imperial
College, London, the Medical Research Council Laboratories,
Cambridge, and the University of California at Davis, where he was
Professor of Biological Chemistry. During his academic career, Dr.
Hanley conducted extensive research in cell signaling, molecular
biology of receptors, and peptide pharmacology. He is widely
published and has been an editorial advisor for numerous journals,
including the Journal of Biological Chemistry and Molecular and
Cellular Endocrinology. Dr. Hanley has served on advisory or review
panels for the National Institutes of Health, the Medical Research
Council and Wellcome Trust of Great Britain, and for the
governments of Australia, Singapore, New Zealand, Hong Kong,
Denmark and Japan. From 1997 to 2003, he was a senior consultant
for healthcare investors in the venture capital and banking
communities and for biotechnology companies such as Cell
Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr.
Hanley has also set-up and directed research programs in
privately-held start-ups, such as Chemocentryx, PsychoGenics, and
most recently Harvard-based Resolvyx Pharmaceuticals. He received a
bachelor's degree in Biochemistry and a Ph.D. in Molecular Biology
from the University of California, Berkeley. Amylin Pharmaceuticals
is a biopharmaceutical company dedicated to developing innovative
medicines to improve the lives of people with metabolic diseases.
The Company's two late-stage, first-in-class diabetes product
candidates -- SYMLIN(R) (pramlintide acetate) and exenatide
(synthetic exendin-4) -- are being developed to address the global
epidemic of diabetes. Amylin has a strategic alliance with Eli
Lilly and Company for the co-development and global
commercialization of exenatide, and an extended release
formulation, exenatide LAR. Building on its experience in the
diabetes field, the Company is developing candidates for
cardiovascular disease and obesity by utilizing its research
experience with the metabolic properties common to all three
conditions. Further information on Amylin and its pipeline in
metabolism is available at http://www.amylin.com/ . This press
release contains forward-looking statements about Amylin, which
involve risks and uncertainties. The Company's actual results could
differ materially from those forward-looking statements discussed
in this press release due to a number of risks and uncertainties,
including risks and uncertainties in the FDA's review process
generally, risks and uncertainties that approval by the FDA, if
any, may be withheld, delayed and/or limited by indications, risks
and uncertainties regarding the drug discovery and development
process, and uncertainties regarding the company's ongoing clinical
studies of its drug candidates, including SYMLIN(R), exenatide and
exenatide LAR. Additional risks and uncertainties are described
more fully in the Company's most recently filed SEC documents, such
as its Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 under the heading "Risk Factors", and its
Quarterly Reports on Form 10-Q. DATASOURCE: Amylin Pharmaceuticals,
Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief
Financial Officer, Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024